Polaryx Therapeutics, Inc. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Polaryx Therapeutics, Inc. (PLYX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$66.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- Polaryx Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $8.00K.
- Polaryx Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$87.00K.
- Polaryx Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was -$66.00K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|
| 2025-12-31 | -$66.00K 10-K · filed 2026-03-24 | ||
| 2025-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$79.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | -$87.00K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |